Skip to content

Folic Acid and Omega -3 Fatty Acid Supplementation in Depressed Older Adults

Randomized Double-blind Controlled Clinical Trial to Assess the Impact of Folic Acid and Omega-3 Fatty Acids Supplementation on the Severity of Depressive Symptoms in Older Adults With Identified Depression

Status
Completed
Phases
Phase 2Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00480207
Enrollment
15
Registered
2007-05-30
Start date
2007-05-31
Completion date
2008-10-31
Last updated
2012-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Brief summary

Our specific aim is to determine the impact of folic acid and omega-3 supplementation on the severity of depressive symptoms among depressed adults aged 65 and above.

Interventions

DIETARY_SUPPLEMENTfolic acid
DIETARY_SUPPLEMENTomega-3
DIETARY_SUPPLEMENTvit B12

Sponsors

The S. Daniel Abraham International Center for Health and Nutrition
CollaboratorOTHER
Prof. RH Belmaker
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
TRIPLE (Subject, Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age 65+ (year of birth -1942 or below) 2. Depression (as defined by the DSM-IV diagnostic criteria for depression: major or minor depression or dysthymia)

Exclusion criteria

1. Co-existing psychiatric disorder (except anxiety disorders) 2. Moderate and severe cognitive impairment 3. Current treatment with anticoagulants, antithrombotics and fibrinolytics 4. Current severe angina with exertion 5. Chronic renal insufficiency 6. Liver cirrhosis 7. Alcohol or drug abuse

Design outcomes

Primary

MeasureTime frame
the severity of depressive symptomsbaseline, 4th , 8th and 12th week

Secondary

MeasureTime frame
cognitive statusbaseline, 4th, 8th, and 12th week
nutritional statusbaseline and end of study
possible side effectsbaseline, 4th, 8th, and 12th week

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026